VANCOCIN HYDROCHLORIDE (vancomycin hydrochloride) by ANI Pharmaceuticals is clinical pharmacology vancomycin is poorly absorbed after oral administration. First approved in 1986.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
VANCOCIN HYDROCHLORIDE is an oral vancomycin formulation, a bactericidal antibiotic that inhibits bacterial cell-wall biosynthesis and alters cell-membrane permeability. It is indicated for treating serious gram-positive infections, particularly Clostridioides difficile infections and methicillin-resistant Staphylococcus aureus (MRSA) when oral therapy is appropriate. The drug has poor systemic absorption when taken orally but achieves high local concentrations in the GI tract.
This product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting the commercial team is likely focused on lifecycle management and generic transition strategies rather than growth.
CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…
Worked on VANCOCIN HYDROCHLORIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VANCOCIN HYDROCHLORIDE offers experience in managing a mature, defensive product through generic transition and competitive commoditization. This role emphasizes pricing strategy, market access, and stakeholder management in a crowded antibiotic space rather than innovation or market expansion.